Clinical Trial

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Study acronym: SHARP
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy of SHR-1701 in combination with SBRT in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-02.
Trial Details
NCT Number NCT07451795
Lead Sponsor Fudan University
Conditions Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Enrollment 66 participants
Start Date 2026-03-02
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30